Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Winter BK, Fiskum G, Gallo LL
Serious side effects are rare when GLP-1 is properly prescribed and monitored
Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 due to preclinical findings of C-cell tumors in rodents[13]
Keywords: glucagon-like peptide-1 receptor agonist, obesity, type 2 diabetes, gastrointestinal adverse events Introduction Diabetes and obesity are increasing at an alarming rate worldwide and placing a significant burden on global healthcare systems
